TULIP1 Anifrolumab RCT in SLE Did NOT meet primary endpt SIR4 wk52 (36% v 40% PLBO, NS) Post Hoc BICLA response DID favor Tx (46% v 30%, NNT~6) Richard Furie: "Medication rules and endpoint selection are critical for SLE trials." Agreed. #ACR19 Abst#1763 #ACRBest @RheumNow https://t.co/R4ily1Ubrz